Search for content, post, videos

Altimmune acquires Spitfire Pharma

The company announced earlier this summer that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH). Spitf
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.